Infliximab for the treatment of resistant oral ulcers in Behçet's disease: A case report and review of the literature

Clinical and Experimental Rheumatology

Volumn 25, Issue 4 SUPPL. 45, 2007, Pages

  Almoznino, Galit ^a   Ben Chetrit, Eldad ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Beh et's disease; Infliximab; Oral ulcers

Indexed keywords

ANESTHETIC AGENT; ANTIBIOTIC AGENT; AZATHIOPRINE; CHLORHEXIDINE; COLCHICINE; CYCLOSPORIN; FLUCONAZOLE; HYDROCORTISONE; INFLIXIMAB; INFUSION FLUID; LIDOCAINE; PREDNISONE; TRECAN; UNCLASSIFIED DRUG; C REACTIVE PROTEIN; HLA B51 ANTIGEN; METHOTREXATE; THALIDOMIDE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; BEHCET DISEASE; CANDIDA GLABRATA; CANDIDIASIS; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLICULITIS; FOLLOW UP; FUNGUS CULTURE; HLA TYPING; HUMAN; LABORATORY TEST; MOUTH ULCER; NONHUMAN; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REMISSION; SINGLE DRUG DOSE; TREATMENT DURATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; ERYTHEMA NODOSUM; ERYTHROCYTE SEDIMENTATION RATE; GENERAL CONDITION IMPROVEMENT; GENITAL ULCER; MIDDLE AGED; MOUTH PAIN; SYSTEMIC THERAPY; THROMBOCYTOSIS; UVEITIS; WEIGHT REDUCTION;

ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; FEMALE; HUMANS; MIDDLE AGED; ORAL ULCER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35448949609     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. YAZICI H: BehA̧et's syndrome: an update. Curr Rheumatol Rep 2003; 5: 195-9.
2. HAMZA M: Pharyngeal stenosis in Behçet's disease. Clin Exp Rheumatol 1988; 6: 139-40.
3. PIPITONE N, OLIVIERI I, CANTINI F, TRIOLO G, SALVARANI C: New approaches in the treatment of Adamantiades-Behçet's disease. Curr Opin Rheumatol 2006; 18: 3-9.
4. ALPSOY E: Behçet's disease: treatment of mucocutaneous lesions. Clin Exp Rheumatol 2005; 23: 532-9.
5. HAMURYUDAN V, OZYAZGAN Y, HIZLI N et al.: Azathioprine in Behçet's syndrome: Effects on long-term prognosis. Arthritis Rheum 1997; 40: 769-74.
6. HAMURYUDAN V, MAT C, SAIP S et al.: Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 443-50.
7. MAT C, YURDAKUL S, UYSAL S et al.: A double-blind trial of depot corticosteroids in Behçet's syndrome. Rheumatology (Oxford) 2006; 45: 348-52.
8. SUZUKI Y, HOSHI K, MATSUDA T, MIZUSHIMA Y: Increased peripheral blood gamma delta+ T cells and natural killer cells in Behçet's disease. J Rheumatol 1992; 19: 588-9.
9. TUGAL-TUTKUN I, MUDUN A, URGANCIOGLU M et al.: Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: An open-label trial. Arthritis Rheum 2005; 52: 2478-84.
10. MELIKOGLU M, FRESKO I, MAT C et al.: Short-term trial of etanercept in Behçet's disease: A double blind, placebo controlled study. J Rheumatol 2005; 32: 98-105.
11. ROBERTSON LP, HICKLING P: Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab. Rheumatology (Oxford) 2001; 40: 473-4.
12. GOOSSENS PH, VERBURG R J, BREEDVELD FC: Remission of Behçet's syndrome with tumour necrosis factor a blocking therapy. Ann Rheum Dis 2001; 60: 637.
13. ESTRACH C, MPOFURS, MOOTS RJ: Behçet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford) 2002; 41: 1213-4.
14. HAUGEBERG G, VELKEN M, JOHNSEN V: Successful treatment of genital ulcers with infliximab in Behȩt's disease. Ann Rheum Dis 2004; 63: 744-5.
15. CONNOLLY M, ARMSTRONG JS, BUCKLEY DA: Infliximab treatment for severe orogenital ulceration in Behçet's disease. Br J Dermatol 2005; 153: 1073-5.
16. SIEPER J, VAN DEN BRANDE J: Diverse effects of infliximab and etanercept on T lymphocytes. Semin Arthritis Rheum 2005; 34 (Suppl.1): 23-7.
17. GOLA: Behçet's disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 2005; 4: 81-3.
18. SFIKAKIS PP, MARCKOMICHELAKIS N, ALPSOY E et al.: Anti TNF therapy in the management of Behçet's disease - review and basis for recommendations, Rheumatology 2007; 46: 736-41.